Berenberg Bank Issues Positive Forecast for Haleon (LON:HLN) Stock Price

Haleon (LON:HLN) had its price objective lifted by Berenberg Bank from GBX 456 ($5.75) to GBX 457 ($5.76) in a report released on Friday morning,Digital Look reports. They currently have a buy rating on the stock.

Haleon Price Performance

Shares of LON:HLN traded up GBX 13.21 ($0.17) during trading on Friday, hitting GBX 408.51 ($5.15). 17,311,160 shares of the company’s stock were exchanged, compared to its average volume of 26,942,223. The business’s 50-day simple moving average is GBX 380.01 and its 200 day simple moving average is GBX 379.31. The company has a market cap of £36.87 billion, a price-to-earnings ratio of 34.36, a PEG ratio of 1.49 and a beta of 0.19. Haleon has a 52-week low of GBX 308.37 ($3.89) and a 52-week high of GBX 411.40 ($5.19). The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93.

Haleon (LON:HLN) last posted its quarterly earnings results on Friday, February 28th. The company reported GBX 15.80 ($0.20) earnings per share for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. As a group, equities analysts predict that Haleon will post 19.5033282 EPS for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.